Morgan Stanley Increases Novartis (NYSE:NVS) Price Target to $170.00

Novartis (NYSE:NVS) had its price objective hoisted by stock analysts at Morgan Stanley from $143.00 to $170.00 in a report released on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 14.64% from the company’s previous close.

Several other equities research analysts have also recently weighed in on NVS. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research report on Thursday, February 12th. Citigroup reissued a “buy” rating on shares of Novartis in a research note on Thursday, February 5th. Weiss Ratings upgraded shares of Novartis from a “buy (b)” rating to a “buy (a-)” rating in a report on Friday, February 6th. JPMorgan Chase & Co. upgraded shares of Novartis from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Finally, HSBC reaffirmed a “reduce” rating and issued a $112.00 price target on shares of Novartis in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Price Performance

Shares of Novartis stock opened at $148.30 on Thursday. The firm has a market cap of $313.26 billion, a PE ratio of 20.71, a PEG ratio of 2.27 and a beta of 0.49. The stock has a 50 day moving average of $155.88 and a 200 day moving average of $139.79. The company has a current ratio of 1.12, a quick ratio of 0.89 and a debt-to-equity ratio of 0.60. Novartis has a 12 month low of $97.71 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.04. The business had revenue of $13.86 billion for the quarter, compared to the consensus estimate of $13.85 billion. Novartis had a return on equity of 40.53% and a net margin of 25.65%.The company’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.98 EPS. On average, research analysts expect that Novartis will post 8.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Novartis

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Arlington Trust Co LLC bought a new position in Novartis during the 4th quarter valued at about $25,000. CrossGen Wealth LLC purchased a new stake in Novartis in the 4th quarter worth about $28,000. Valley Wealth Managers Inc. bought a new stake in Novartis in the third quarter worth about $31,000. Bank of Jackson Hole Trust lifted its stake in Novartis by 425.0% in the fourth quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 187 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in shares of Novartis during the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Strategic pipeline lift — acquisition adds Exl‑111, a next‑generation anti‑IgE candidate designed to dissociate receptor‑bound IgE and potentially deliver faster, deeper suppression across food allergy, urticaria and asthma; strengthens Novartis’ allergy franchise and long‑term growth optionality. Novartis press release
• Positive Sentiment: Third‑party validation of strategic rationale — Zacks and other outlets highlight the deal as a targeted move to shore up Novartis’ immunology/allergy pipeline, giving the company a potentially differentiated asset in an established biology area. Zacks: Novartis bolsters immunology pipeline
• Positive Sentiment: Analyst upgrade/price target lift — Morgan Stanley raised its price target to $170 and moved to overweight, suggesting upside based on the company’s pipeline and strategic M&A. That supports a constructive medium‑term view despite near‑term noise. Benzinga: Morgan Stanley raises PT
• Neutral Sentiment: Deal terms and timing — Novartis will pay up to $2.0B in upfront and milestone payments; transaction expected to close in H2 2026 subject to customary conditions. That sets clear milestone watches but implies multi‑year value realization. Reuters: Deal terms
• Negative Sentiment: Analyst caution on execution and timing — Goldman Sachs (via TipRanks) kept a Sell rating, citing long‑dated pipeline risk and looming loss‑of‑exclusivity (LOE) headwinds that the Excellergy add does not immediately offset; some investors may view the deal as expensive for an early‑stage asset. TipRanks: Goldman Sachs reaction

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.